EUROPLASMA announces the postponement of the publication of the 2023 financial statements

Europlasma, a company active in the treatment of hazardous waste, has postponed the release of its financial statements for the year 2023, initially scheduled for today. This postponement follows the recent acquisition of MG-Valdunes, approved on March 20 by the Commercial Court. The company is reviewing the financial implications of this acquisition and adjusting its strategies to ensure balanced financial management.

The initial report indicates a turnover of 15.4 million euros, marking an increase of 6% compared to the previous year. However, EBITDA remains negative at -13 million euros, and net profit stands at -14.7 million euros. Cash flow is also down, going from 2.4 million euros at the end of 2022 to 1.2 million euros at December 31, 2023.

Europlasma will communicate the new publication dates of the financial results and the general meeting as soon as possible. A further postponement after June 30 will also be announced if necessary.